CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. - sprookjes - yvandenbroek - TriplyDB

CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.

CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.

http://www.wikidata.org/entity/Q34299986

about

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy Adoptive T-cell therapy for cancer: The era of engineered T cells Acquired and intrinsic resistance in cancer immunotherapy Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook Leveraging fluorinated glucosamine action to boost antitumor immunity To affinity and beyond: harnessing the T cell receptor for cancer immunotherapy Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic T-cell receptor gene therapy--ready to go viral?Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies Melanoma NOS1 expression promotes dysfunctional IFN signaling CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.High sensitivity of cancer exome-based CD8 T cell neo-antigen identification Immunotherapy for metastatic solid cancers Circulating Type-1 Anti-Tumor CD4(+) T Cells are Preferentially Pro-Apoptotic in Cancer Patients.Adoptive immunotherapy with Cl-IB-MECA-treated CD8+ T cells reduces melanoma growth in mice Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway.Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.Therapeutic cancer vaccines: are we there yet?The tumor targeted superantigen ABR-217620 selectively engages TRBV7-9 and exploits TCR-pMHC affinity mimicry in mediating T cell cytotoxicity.Adoptive cell therapy for patients with melanoma.Mouse model for pre-clinical study of human cancer immunotherapy.Combination of IFNα and poly-I:C reprograms bladder cancer microenvironment for enhanced CTL attraction.Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.Treating cancer with genetically engineered T cells.Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement A high-throughput RNAi screen for detection of immune-checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma Combined Tbet and IL12 gene therapy elicits and recruits superior antitumor immunity in vivo.Evaluation of γ-retroviral vectors that mediate the inducible expression of IL-12 for clinical application.New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer Memory T cells are uniquely resistant to melanoma-induced suppression.Trial Watch: Adoptive cell transfer immunotherapy.TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients.Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer.Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor.Tumor-infiltrating lymphocytes in melanoma.Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes

P2860

Q24596055-CF36E804-EA83-4B4E-9912-04514F401534 Q26800611-30F033B5-2FFD-4044-A637-3B11822F10E7 Q26827701-6420829A-034E-40FB-8B4C-6237F7600CD0 Q27002575-C1625109-BD4D-4EA2-96CA-2B9F3E551B3D Q27004178-1F6C120D-B24B-4BC3-9506-704E80C96845 Q27008230-E4FFD010-BE19-4142-A9D3-71F8111AC489 Q27008423-39AEAB15-F90E-479E-81BF-9FCEB41F4A96 Q27686800-997E0EC0-51F8-4C9F-9BF9-CC0984EBB924 Q28075992-B00CAEF2-F253-4698-8FE4-613F52532E15 Q28081611-DB61DD41-4563-47AB-A24D-BC6851DAF242 Q28085769-CF3A169F-E65D-4606-9B21-43F259A379AE Q30413226-A97E4CA2-489C-4146-8375-444A2DBE7BD5 Q30573747-90C397F4-F3F0-4ADC-8900-68417ED68907 Q33930588-CB99AEDA-F98E-48FE-8EED-EA2F3213DC8B Q34219970-209DBA73-C774-4D2E-8E47-936AFC46D909 Q34259974-02AEC706-48A5-4AEE-843B-916EE4716D70 Q34428963-AB723218-2E34-42DF-A86B-04A1CDE78E05 Q34458364-92813278-0227-47FD-A2FA-2A119D90E9A3 Q34757266-E2B58D5C-9C37-4EC6-8870-947C42AAFBE2 Q34786691-FA53E646-818A-486A-AB76-3758810F173C Q35032671-124D68DC-A02C-493A-96DD-40F5812292BE Q35057983-7F8B3A1F-FC14-498A-89A3-324326FD01E9 Q35181705-0B1285AB-809F-4F33-9487-8273B2C721A2 Q35212274-CF71C989-A445-457D-8123-D90A3F14A873 Q35223241-A0FA62CE-898E-4528-B171-58E9824E09F0 Q35353365-37450C00-73FF-40FE-8442-7022B3A44B6F Q35382043-89F311BF-736A-4E89-85A2-3D35B94F58F8 Q35483823-E8A8B491-2099-4C70-9B53-4FE8A361B1A1 Q35507358-BECF6B5B-025D-4124-998E-B16E1744A29D Q35677962-2E515966-62F1-432C-879B-92ADC376A5E5 Q35802152-3905C308-BCFD-4612-A720-3F3C684BF307 Q35982211-D73718DE-5BFB-41AC-841E-5B0CAC980B35 Q35996395-98422BE1-6C9C-445D-8D13-A0786CE6BF36 Q35997789-5334D390-E348-476A-A456-2670B52D8DE0 Q36057432-1D7E83AA-0DDF-4AA7-B47E-6F349FA3F392 Q36057454-AF13BAA8-6EA8-488E-AD41-CE6BBEC7B77E Q36057563-855C118A-5C39-45EF-B7E3-EAD370F94747 Q36110862-418ABA13-D81B-44F2-B4A6-28A3CDD5EEAB Q36292200-8E9EE4AB-91AA-465B-9051-342702E14DD8 Q36340598-C8DC9D35-6D51-448E-85AA-3181019FBFA7

P2860

CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.

http://www.wikidata.org/entity/Q34299986

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

CD8+ enriched "young" tumor in ...... ession of metastatic melanoma.

@ast

CD8+ enriched "young" tumor in ...... ession of metastatic melanoma.

@en

CD8+ enriched "young" tumor in ...... ession of metastatic melanoma.

@nl

type

label

CD8+ enriched "young" tumor in ...... ession of metastatic melanoma.

@ast

CD8+ enriched "young" tumor in ...... ession of metastatic melanoma.

@en

CD8+ enriched "young" tumor in ...... ession of metastatic melanoma.

@nl

prefLabel

CD8+ enriched "young" tumor in ...... ession of metastatic melanoma.

@ast

CD8+ enriched "young" tumor in ...... ession of metastatic melanoma.

@en

CD8+ enriched "young" tumor in ...... ession of metastatic melanoma.

@nl

P1433

Q34299986-7AEFA166-4677-4A1A-91CC-DA54AD107772

P1476

Q34299986-39EF046C-3BD1-469E-8902-DEC30B5A36EF

P2093

Q34299986-0BF8E967-0DC5-42A6-9C0E-21DE297E80A0

Q34299986-11EF5556-E3F8-4017-A2A9-F2E1524125E0

Q34299986-1F48EAA3-0AC2-4E93-BB74-D5AC5391FD8C

Q34299986-24BFF70E-F177-49CC-96DC-6F2F79537FBF

Q34299986-2A1CD99E-8F16-4B10-8CA6-8F1146349276

Q34299986-50D02039-AE36-4E39-8223-B1DFB357D401

Q34299986-6727893C-37C8-4589-86F8-24E973D3E666

Q34299986-71540616-A681-4FD1-AEAA-4FA89F70EF07

Q34299986-7F503E7D-C104-40F7-BCF3-02BE316B0389

Q34299986-8C9FC8FC-9D58-46AC-A036-D29BE31904D0

P2860

Q34299986-02B6E398-6EBF-4D2B-AF1F-BA79B758F570

Q34299986-10FEEB96-F7B8-4110-A985-286C807B1D43

Q34299986-15C968E9-7B58-4AB9-9FFF-85DD72C33A62

Q34299986-17FCC5AC-FB48-44F0-870C-21DE186BE031

Q34299986-269AF7D7-F788-4DF5-ADC4-07394D9FB308

Q34299986-2E28D467-7404-42F9-82D8-9EFAD19EB6A7

Q34299986-42B7F01F-1DF9-4269-9914-60575E924E32

Q34299986-43FF327D-CEB3-4747-AAAA-7CBE1537A956

Q34299986-508CB39E-7051-4F94-AA15-3B61A8313F39

Q34299986-51F73607-142F-452B-BDCA-504092A7DE69

P304

Q34299986-B967A720-6649-4BAE-B253-D1AB543154EB

P31

Q34299986-F7D68331-91B3-4831-BEC4-31238FCD7EDB

P356

Q34299986-49E5E84C-4F5B-4010-8D71-1AA6470FAC71

P407

Q34299986-1104E618-3DCD-49A1-80AB-056972F4565A

P433

Q34299986-1CB8487F-2CB6-4EB1-B30B-E6809AB60D8C

P478

Q34299986-B845E7F9-AF7E-4971-8722-F3E73B4F6BC9

P577

Q34299986-8F80DF84-C8AE-4D01-A46F-F02D12920024

P5875

Q34299986-1B454594-B53B-4C7E-B879-A5C395572CAE

P698

Q34299986-0C8E4215-00B2-4E00-BC8F-009E0169C1EE

P932

Q34299986-64DD8743-E988-43DA-9233-CAA156D84841

P356

1078-0432.CCR-10-1297

P1433

Clinical Cancer Research

P1476

CD8+ enriched "young" tumor in ...... ession of metastatic melanoma.

@en

P2093

Carolyn M Laurencot

http://www.w3.org/2001/XMLSchema#string

Colin A Gross

http://www.w3.org/2001/XMLSchema#string

Daniel A Zlott

http://www.w3.org/2001/XMLSchema#string

Deborah E Citrin

http://www.w3.org/2001/XMLSchema#string

Donald E White

http://www.w3.org/2001/XMLSchema#string

Giao Q Phan

http://www.w3.org/2001/XMLSchema#string

James C Yang

http://www.w3.org/2001/XMLSchema#string

Jenny J Hong

http://www.w3.org/2001/XMLSchema#string

John R Wunderlich

http://www.w3.org/2001/XMLSchema#string

Kathleen E Morton

http://www.w3.org/2001/XMLSchema#string

P2860

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

P304

6122-6131

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-10-1297

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45406384

http://www.w3.org/2001/XMLSchema#string

P698

20668005

http://www.w3.org/2001/XMLSchema#string

P932

2978753

http://www.w3.org/2001/XMLSchema#string